All Title Author
Keywords Abstract

Trials  2010 

The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial

DOI: 10.1186/1745-6215-11-122

Full-Text   Cite this paper   Add to My Lib

Abstract:

The present study aims to investigate differences in occurrence of CIN after sarpogrelate premedication in patients with chronic kidney disease (CKD). 268 participants, aged 20-85 years with a clinical diagnosis of CKD will be recruited. They will be randomly allocated to one of two conditions: (i) routine treatment without sarpogrelate, and (ii) routine treatment with sarpogrelate (a fixed-flexible dose of 300 mg/day). The primary outcome is the occurrence of CIN during 4 weeks after receiving contrast agent.As of May 2010, there were no registered trials evaluating the therapeutic potentials of sarpogrelate in preventing for CIN. If sarpogrelate decreases the worsening of renal function and occurrence of CIN, it will provide a safe, easy and inexpensive treatment option.NCT01165567Contrast-induced nephropathy (CIN) is a common form of hospital-acquired acute renal failure (ARF) after coronary angiography (CAG) and percutaneous coronary intervention (PCI) and is associated with prolonged hospitalization and adverse clinical outcomes [1,2]. Patients undergoing PCI have a higher mortality rate if the nephropathy develops [3]. Although its incidence is low in patients with normal renal function, it can be much higher in those with renal insufficiency at baseline [4,5]. Adequate prophylaxis is needed to reduce the higher morbidity and mortality associated with CIN in high-risk patients. A variety of therapeutic interventions, including saline hydration, diuretics, mannitol, calcium channel antagonists, theophylline, endothelin receptor antagonists, and dopamine, have been used in an attempt to prevent CIN [6-9]. Hydration with normal saline solution is the most widely accepted preventive intervention [9,10]. But the nephropathy occurred in 20~30% who received the recommend treatment [11,12], it means current treatments are not enough and the optimal strategy to prevent CIN has not been established.Although the pathogenesis of this condition is not fully understood, it

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal